Based on our in vitro findings in GCT and early clinical experience of EpCAM-redirected immunotherapy in other epithelial EpCAM-positive cancer entities, such therapeutics may also prove beneficial for the treatment of cisplatin-resistant GCT and warrant clinical exploration. The gene discussed is EPCAM; the disease is cancer.